Hedgehog inhibitors: a patent review (2013 – present)

Bibliography

• Rask-Anderson M, Zhang J, Fabbro D, et al. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci 2014;35:604-20
   PubMedGoogle Scholar
• Ng JM, Curran T. The Hedgehog’s tale: developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493-501
   PubMed Web of Science ®Google Scholar
• Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs 2013;73:1-11
   PubMedGoogle Scholar
• Onishi H, Katano M. Hedgehog signaling pathway as therapeutic target in various types of cancer. Cancer Sci 2011;102:1756-60
   PubMedGoogle Scholar
• Mahindroo N, Punchihewa C, Fujii N. Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J Med Chem 2009;52:3829-45
   PubMed Web of Science ®Google Scholar
• Tremblay MR, Nesler M, Weatherhead R, et al. Recent patents for hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Pat 2009;19:1039-56
   PubMed Web of Science ®Google Scholar
• Peukert S, Miller-Moslin K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem 2010;5:500-12
   PubMed Web of Science ®Google Scholar
• Li Y, Maitah MY, Ahmad A, et al. Targeting the hedgehog signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:49-66
   PubMed Web of Science ®Google Scholar
• Hadden MK. Hedgehog pathway inhibitors: a patent review (2009 - present). Expert Opin Ther Pat 2013;23:345-61
   PubMed Web of Science ®Google Scholar
• Banerjee U, Hadden MK. Recent advances in the design of hedgehog pathway inhibitors for the treatment of malignancies. Expert Opin Drug Discov 2014;9:751-71
   PubMed Web of Science ®Google Scholar
• Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in drosophila. Nature 1980;287:795-801
   PubMed Web of Science ®Google Scholar
• Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 1993;75:1417-30
   PubMed Web of Science ®Google Scholar
• Trinh TN, McLaughlin EA, Gordon CP, et al. Hedgehog signaling pathway inhibitors as cancer suppressing agents. Med Chem Comm 2014;5:117-33
   Web of Science ®Google Scholar
• Rohatgi R, Milenkovic L, Corcoran RB, et al. Hedgehog signal transduction by Smoothened: pharmacological evidence for a 2-step activation process. Proc Natl Acad Sci USA 2009;106:3196-201
   PubMed Web of Science ®Google Scholar
• Tremblay MR, McGovern K, Read MA, et al. New developments in the discovery of small molecule hedgehog pathway antagonists. Curr Opin Chem Biol 2010;10:428-35
   Google Scholar
• Rubin LL, de Sauvage FJ. Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026-33
   PubMed Web of Science ®Google Scholar
• Scales SJ, de Sauvage FJ. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30:303-12
   PubMed Web of Science ®Google Scholar
• Gupta S, Takebe N, Lorusso P. Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol 2010;2:237-50
   PubMedGoogle Scholar
• Amakye D, Jaqani Z, Dorsch M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat Med 2013;19:1410-22
   PubMed Web of Science ®Google Scholar
• Gould A, Missailidis S. Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway. Mini Rev Med Chem 2011;11:200-13
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152:43-51
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488:106-10
   PubMed Web of Science ®Google Scholar
• Jones DT, Jager N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012;488:100-5
   PubMed Web of Science ®Google Scholar
• Rajurkar M, Huang H, Cotton JL, et al. Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis. Oncogene 2014;33:5370-8
   PubMedGoogle Scholar
• Hettmer S, Teot LA, van Hummelen P, et al. Mutations in Hedgehog pathway genes in fetal rhabdomyomas. J Pathol 2013;231:44-52
   PubMedGoogle Scholar
• Singh S, Wang Z, Liang FD, et al. Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res 2011;71:4454-63
   PubMedGoogle Scholar
• Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455:406-10
   PubMed Web of Science ®Google Scholar
• Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007;13:944-51
   PubMed Web of Science ®Google Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-19
   PubMed Web of Science ®Google Scholar
• Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40
   PubMed Web of Science ®Google Scholar
• Teperino R, Aberger F, Esterbauer H, et al. Canonical and non-canonical hedgehog signaling and the control of metabolism. Semin Cell Dev Biol 2014;33:81-92
   PubMed Web of Science ®Google Scholar
• Teperino R, Amann S, Bayer M, et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell 2012;151:414-26
   PubMed Web of Science ®Google Scholar
• Eberl M, Klingler S, Mangelberger D, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumor-initiating pancreatic cancer cells. EMBO Mol Med 2012;4:218-33
   PubMed Web of Science ®Google Scholar
• Nolan-Stevaux O, Lau J, Truitt ML, et al. Gli1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009;23:24-36
   PubMed Web of Science ®Google Scholar
• Brennan D, Chen X, Cheng L, et al. Noncanonical hedgehog signaling. Vitam Horm 2012;88:55-72
   PubMed Web of Science ®Google Scholar
• Robarge KD, Brunton SA, Castanedo GE, et al. GDC-0449-A potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009;19:5576-81
   PubMed Web of Science ®Google Scholar
• Lyons TG, O’Kane GM, Kelly CM. Efficacy and safety of vismodegib: a new therapeutic agents in the treatment of basal cell carcinoma. Expert Opin Drug Saf 2014;13:1125-32
   PubMed Web of Science ®Google Scholar
• A search results of the clinical information for GDC-0449(Vismodegib) ongoing. Available from: http://www.clinicaltrials.gov/ct2/results?term=vismodegib&Search=Search
   Google Scholar
• Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 2010;1:130-4
   PubMed Web of Science ®Google Scholar
• Wang C, Wu H, Katritch V, et al. Structure of the human smoothened receptor bound to an antitumor agent. Nature 2013;497:338-43
   PubMed Web of Science ®Google Scholar
• Rocconi RP, Samant L. Methods and compositions for the treatment of ovarian cancer. WO943255; 2013
   Google Scholar
• Munchhof MJ, Li Q, Shavnya A, et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett 2012;3:106-11
   PubMed Web of Science ®Google Scholar
• Peukert S, He F, Dai M, et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem 2013;8:1261-5
   PubMed Web of Science ®Google Scholar
• Tremblay MR, Lescarbeau A, Grogan MJ, et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009;52:4400-18
   PubMed Web of Science ®Google Scholar
• Allison M. Hedgehog hopes lifted by approval and stung by failure. Nat Biotechnol 2012;30:203
   PubMedGoogle Scholar
• Wagner AHP, Okuno S, Eriksson M, et al. Results from a phase 2 randomized, placebo-controlled, double blind study of the hedgehog (HH) pathway antagonist IPI-926 in patients (PTS) with advanced chondrosarcoma (CS). Connective tissue oncology society 18th annual meeting; New York; 2013
   Google Scholar
• Ohashi T, Oguro Y, Tanaka T, et al. Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors. Bioorg Med Chem 2012;20:5496-506
   PubMed Web of Science ®Google Scholar
• Ohashi T, Oguro Y, Tanaka T, et al. Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]quinoline-4-one derivative as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. Bioorg Med Chem 2012;20:5507-17
   PubMed Web of Science ®Google Scholar
• Ishii T, Shimizu Y, Nakashima K, et al. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against vismodegib-resistant smoothened mutant. Eur J Pharmacol 2014;723:305-13
   PubMed Web of Science ®Google Scholar
• Miller-Moslin K, Peukert S, Jain RK, et al. 1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem 2009;52:3954-68
   PubMed Web of Science ®Google Scholar
• Castanedo GM, Wang S, Robarge KD, et al. Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway. Bioorg Med Chem Lett 2010;20:6748-53
   PubMedGoogle Scholar
• Malancona S, Altamura S, Filocamo G, et al. Identification of MK-5710 ((8aS)-8a-methyl-1,3- dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1Hpyrazol-5-yl)hexahydroimidazo[1,5-a] pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 1. Bioorg Med Chem Lett 2011;21:4422-8
   PubMed Web of Science ®Google Scholar
• Kinzel O, Alfieri A, Altamura S, et al. Identification of MK-5710 ((8aS)-8amethyl-1,3-dioxo-2- [(1S,2R)-2-phenylcyclo-propyl]-N-(1-phenyl-1Hpyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine -7(1H)-carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 2. Bioorg Med Chem Lett 2011;21:4429-35
   PubMed Web of Science ®Google Scholar
• Brown ML, Aaron W, Austin RJ, et al. Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hit. Bioorg Med Chem Lett 2011;21:5206-9
   PubMedGoogle Scholar
• Ontoria JM, Bufi LL, Torrisi C, et al. Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4- oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors. Bioorg Med Chem Lett 2011;21:5274-82
   PubMed Web of Science ®Google Scholar
• Muraglia E, Ontoria JM, Branca D, et al. N-(2-alkylaminoethyl)-4-(1,2,4-oxadiazol-5-yl) piperazine-1-carboxamides as highly potent smoothened antagonists. Bioorg Med Chem Lett 2011;21:5283-8
   PubMed Web of Science ®Google Scholar
• Wang J, Jr Mook RA, Lu J, et al. Identification of a novel smoothened antagonist that potently suppresses hedgehog signaling. Bioorg Med Chem Lett 2012;20:6751-7
   Google Scholar
• Yang B, Hird AW, Russell DJ, et al. Discovery of novel hedgehog antagonists from cell-based screening: isosteric modification of p38 bisamides as potent inhibitors of SMO. Bioorg Med Chem Lett 2012;22:4907-11
   PubMedGoogle Scholar
• Manzetti F, Faure H, Roudaut H, et al. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family of smoothened antagonists. Mol Pharm 2010;78:658-65
   Google Scholar
• Solinas A, Faure H, Roudaut H, et al. Acylthiourea, acylurea, and acylquanidine derivatives with potent hedgehog inhibiting activity. J Med Chem 2012;55:1559-71
   PubMed Web of Science ®Google Scholar
• Centre National de la Recherche Scientifique. N-acylthiourea and Nacylurea inhibitors of the hedgehog protein signalling pathway. WO130422; 2009
   Google Scholar
• Centre National de la Recherche Scientifique. Acyl guanidine derivatives modulating the hedgehog protein signaling pathway. WO010013; 2011
   Google Scholar
• Manzetti F, Faure H, Roudaut H, et al. Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family of smoothened antagonists. Mol Pharm 2010;78:658-65
   Google Scholar
• Centre National de la Recherche Scientifique. Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications. WO042082; 2013
   Google Scholar
• Duke University. Preparation of Smoothened modulators for treatment of proliferative disease. WO043608; 2014
   Google Scholar
• Impact Therapeutics, Inc. 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino) isoquinoline as hedgehog pathway inhibitor and use thereof. WO013614; 2013
   Google Scholar
• Impact Therapeutics, Inc. Preparation of N-(3-heteroarylaryl)-4-arylarylcarboxamides as hedgehog pathway inhibitors for treatment of cancer. WO012511; 2014
   Google Scholar
• Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrimidinamines and pyridylamines as inhibitors for hedgehog signaling conduction and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN103864770; 2012
   Google Scholar
• Jiangsu Simcere Pharmaceutical Co., Ltd. Preparation of dihydropyranopyrimidine derivatives as Hedgehog signaling inhibitor. CN103910736; 2013
   Google Scholar
• Jiangsu Simcere Pharmaceutical Co., Ltd. Preparation of heterocyclic compounds as hedgehog signaling path inhibitors. CN104003990; 2013
   Google Scholar
• Xin M, Wen J, Tang F, et al. The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as Potent Hedgehog Signaling Pathway Inhibitors. Bioorg Med Chem Lett 2013;23:6777-83
   PubMed Web of Science ®Google Scholar
• Xin M, Wen J, Tang F, et al. Synthesis and evaluation of N-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway. Bioorg Med Chem Lett 2014;24:983-8
   PubMed Web of Science ®Google Scholar
• Xin M, Zhang L, Tang F, et al. Design, synthesis and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors. Bioorg Med Chem 2014;22:1429-40
   PubMed Web of Science ®Google Scholar
• Xin M, Zhang L, Shen H, et al. Design, synthesis, and biological study of 6,7-dihydro-5H-pyrano[2,3-d]pyrimidine derivatives as novel hedgehog signaling pathway inhibitors. Med Chem Res 2014;23:3784-92
   Web of Science ®Google Scholar
• Zhang L, Xin M, Shen H, et al. Five-membered heteroaromatic ring fused-pyrimidine derivatives: design, synthesis, and hedgehog signaling pathway inhibition study. Bioorg Med Chem Lett 2014;24:3486-92
   PubMedGoogle Scholar
• Zhang L, Xin M, Wen J, et al. 4-(Pyrimidin-2-ylamino)benzamide derivatives: design, synthesis, and hedgehog signaling pathway inhibition study. Chin J Org Chem 2014;34:1407-16
   Google Scholar
• Kunming Institute of Botany, Chinese Academy of Sciences, P. R. China. Application of rubia alata cyclopeptides as hedgehog signaling path inhibitor, and their preparation methods and application. CN103877562; 2014
   Google Scholar
• Memorial Sloan-kettering Cancer Center, The Rochefeller University. Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines. WO142253; 2013
   Google Scholar
• Petrova E, Rios-Esteves J, Ouerfelli O, et al. Inhibitors of hedgehog acyltransferase block sonic hedgehog signaling. Nat Chem Biol 2013;9:247-9
   PubMed Web of Science ®Google Scholar
• Nanjing Huawei Pharmaceutical Science and Technology Development Co., Ltd. Preparation of multiple-target antitumor compounds and useful in the treatment of cancer. CN103923066; 2014
   Google Scholar
• Nant Holdings IP, LLC. Preparation of cyclic sulfonamide derivatives as inhibitors of hedgehog signaling pathway. WO071298; 2014
   Google Scholar
• President and Fellow of Harvard College. Modulators of hedgehog signaling pathway. US0274233; 2013
   Google Scholar
• Wang Y, Arvanites AC, Davidow L, et al. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem Biol 2012;7:1040-8
   PubMed Web of Science ®Google Scholar
• Sichuan University. Preparation of signaling pathway inhibitors for treating tumors and osteoporosis. CN103040824; 2013
   Google Scholar
• Wu TM, Wang DC, Xiang P, et al. Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists. Bioorg Med Chem Lett 2014;24:1426-31
   PubMedGoogle Scholar
• Suzhou Yunxuan Pharmaceutical Co., Ltd. Aminothiazole-pyridine heterocyclic compounds as hedgehog pathway antagonists and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN103524535; 2013
   Google Scholar
• Suzhou Yunxuan Pharmaceutical Co., Ltd. Pyrimidine derivatives as hedgehog pathway antagonists and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN103588771; 2013
   Google Scholar
• Suzhou Yunxuan Pharmaceutical Co., Ltd. Preparation of pyridine heterocyclic compounds with hedgehog pathway antagonist activity. CN103923085; 2014
   Google Scholar
• Xiaohu Z. Hedgehog pathway signaling inhibitors and therapeutic applications thereof. WO113191; 2014
   Google Scholar
• Rohner A, Spilker ME, Lam JL, et al. Effective targeting of hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther 2012;11:57-65
   PubMed Web of Science ®Google Scholar
• Betti M, Castagnoli G, Panico A, et al. Development of a scalable route to the SMO receptor antagonist SEN794. Org Process Res Dev 2012;16:1739-45
   Google Scholar
• Lu W, Geng D, Sun Z, et al. Scaffold hopping approach to a new series of smoothened antagonist. Bioorg Med Chem Lett 2014;24:2300-4
   PubMedGoogle Scholar
• Ma H, Lu W, Sun Z, et al. Design, synthesis, and structure-activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists. Eur J Med Chem 2015;89:721-32
   PubMedGoogle Scholar
• The Board of Trustees of The Leland Stanford Junior University. Imidazo bicycle imminium compounds as antitumor agents. WO192301; 2013
   Google Scholar
• The Regents of The University of California. Targeting Gli proteins in human cancer by small molecules. WO013190; 2013
   Google Scholar
• The Regents of The University of California. Targeting Gli proteins in human cancer by small molecules. WO116651; 2014
   Google Scholar
• Bosco-Clement G, Zhang F, Chen Z, et al. Targeting gli transcription activation by small molecule suppresses tumor growth. Oncogene 2014;33:2087-97
   PubMed Web of Science ®Google Scholar
• Yauch RL, Dijkgraaf GJP, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4
   PubMed Web of Science ®Google Scholar
• Buonamici S, Williams J, Morriessey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70
   PubMed Web of Science ®Google Scholar
• Wang CYY, Wei Q, Han I, et al. Hedgehog and notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. Cancer Res 2012;72:1013-22
   PubMed Web of Science ®Google Scholar
• Jesus-Acosta AD, O’Dwyer PJ, Ramanathan RK, et al. A phase II study of vismodegib, a hedgehog (hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 2014;32(Suppl 3):abstract 257
   Google Scholar